Jaguar Health, INC 8-K filings

Jaguar Health, Inc. completed a private placement of Series N Perpetual Preferred Stock, raising approximately $2.38 million for working capital and debt repayment.

Jaguar Health, Inc. announced that its stockholders approved all seven proposals at the 2025 Annual Meeting, including director elections and share issuance authorizations.

Jaguar Health, Inc. amended its At-the-Market Offering Agreement to extend Lucid Capital Markets' role as a manager until December 31, 2025.

Jaguar Health, Inc. has reduced its outstanding royalty interest obligations by $6.5 million through the issuance of Series M Perpetual Preferred Stock to Iliad Research and Trading, L.P. and Streeterville Capital, LLC.

Jaguar Health, Inc. announced a debt restructuring that extends the maturity of approximately $2.57 million in convertible promissory notes to January 30, 2026, and includes the issuance of new warrants to participating investors, including company insiders.

Jaguar Health, Inc. has entered into agreements for a registered direct offering of 246,306 common shares at $6.09 per share, alongside unregistered warrants, to raise approximately $1.5 million.

Jaguar Health's Q1 2025 financials reveal a decrease in overall prescription product revenue, though Mytesi prescription volume saw a slight increase year-over-year.

Jaguar Health is pursuing multiple growth opportunities, including rare disease treatments and expansion of its existing product lines, supported by recent positive clinical data and strategic partnerships.

Jaguar Health obtains a limited waiver from investors to proceed with an at-the-market offering, despite a previous agreement restricting variable rate transactions.

Jaguar Health issued 57,500 shares of common stock to reduce its royalty interest by $632,500.

Jaguar Health reports that crofelemer shows promise in reducing the need for parenteral nutrition in patients with Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF).

Jaguar Health will host an investor webcast on April 30, 2025, to discuss preliminary results from a proof-of-concept trial of crofelemer for microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).

Jaguar Health files an amendment to its original 8-K report to correct the date of the earliest reported event and restates information regarding a note amendment with Streeterville Capital and an exchange agreement involving the issuance of common stock.

Jaguar Health is pursuing growth through rare disease programs, potential business development deals, and expansion of its crofelemer pipeline, as highlighted in its latest investor presentation.

Jaguar Health is focusing on rare disease treatments and exploring business development opportunities, highlighted by upcoming presentations and clinical trial data.

Jaguar Health secures $3.4 million through a private placement of convertible notes and warrants to fund working capital and advance crofelemer development.

Jaguar Health announces a 20% increase in net revenue for 2024, reaching $11.7 million, driven by prescription and non-prescription product sales.

Jaguar Health announces a $3.448 million private placement of convertible promissory notes to fund working capital and general corporate purposes, with participation from key company insiders and accredited investors.

Jaguar Health has implemented a 1-for-25 reverse stock split to meet Nasdaq listing requirements and attract institutional investors.

Jaguar Health announces stockholder approval of proposals for a reverse stock split and meeting adjournment, alongside updates on clinical trials and regulatory pathways for crofelemer.

Jaguar Health adopts a limited duration stockholder rights plan to protect long-term stockholder value amid acquisition interest and upcoming clinical trial results.

Jaguar Health and its subsidiary Napo Pharmaceuticals amend a secured promissory note with Streeterville Capital, extending the maturity date to January 20, 2026.

Jaguar Health extends the maturity date of its secured promissory note with Streeterville Capital and reduces its royalty interest by issuing shares of common stock.

Jaguar Health has extended its agreement with Lucid Capital Markets to continue as a manager for its at-the-market offering until November 30, 2024.

Jaguar Health announced a 14% increase in Q3 2024 revenue compared to Q2 2024, driven by growth in prescription and non-prescription product sales, and provided updates on its clinical programs.

Jaguar Health announced a 16% increase in Q2 2024 revenue compared to Q1 2024, driven by prescription and non-prescription product sales, and is planning an October 2024 launch for Gelclair.

Jaguar Health's Phase 3 OnTarget trial for crofelemer did not meet its primary endpoint across all tumor types, but showed clinically relevant signals in breast and respiratory cancer subgroups.

Jaguar Health has amended its At-the-Market Offering Agreement to include Lucid Capital Markets as a manager alongside Ladenburg Thalmann, effective until September 30, 2024, unless extended.

Jaguar Health, Inc. issued 455,000 shares of common stock to reduce its royalty debt by $1,851,850.

Jaguar Health has regained compliance with Nasdaq's minimum bid price requirement and is set to report pivotal phase 3 trial results for its cancer supportive care drug, crofelemer, by July 23, 2024.